Lineage Cell Therapeutics, Inc. (LCTX)

NYSEAMERICAN: LCTX · Real-Time Price · USD

1.570

-0.010 (-0.63%)

At close: Jan 29, 2026, 4:00 PM EST

1.560

-0.010 (-0.64%)

After-hours: Jan 29, 2026, 6:47 PM EST

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jan '26 Jan 29, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	380	111	191	199	413	264	Upgrade
Market Cap Growth	236.39%	-41.93%	-4.09%	-51.84%	56.44%	98.01%	Upgrade
Enterprise Value	343	79	151	134	349	228	Upgrade
Last Close Price	1.58	0.50	1.09	1.17	2.45	1.76	Upgrade
PS Ratio	33.73	11.66	21.32	13.53	95.13	144.57	Upgrade
PB Ratio	16.51	1.44	3.08	2.77	4.54	2.78	Upgrade
P/TBV Ratio	-	5.23	30.84	12.45	11.89	6.86	Upgrade
P/FCF Ratio	-	-	-	307.85	-	-	Upgrade
P/OCF Ratio	-	-	-	187.79	-	-	Upgrade
EV/Sales Ratio	31.67	8.36	16.88	9.11	80.50	124.70	Upgrade
EV/FCF Ratio	-	-	-	207.31	-	-	Upgrade
Debt / Equity Ratio	0.13	0.03	0.05	0.05	0.03	0.04	Upgrade
Debt / FCF Ratio	-	-	-	6.03	-	-	Upgrade
Asset Turnover	0.12	0.09	0.08	0.10	0.03	0.02	Upgrade
Quick Ratio	4.33	3.47	2.02	3.07	2.32	5.35	Upgrade
Current Ratio	4.50	3.65	2.14	3.16	2.37	5.66	Upgrade
Return on Equity (ROE)	-157.75%	-26.73%	-32.07%	-32.37%	-46.52%	-20.05%	Upgrade
Return on Assets (ROA)	-13.65%	-12.53%	-11.80%	-9.44%	-21.77%	-14.16%	Upgrade
Return on Capital Employed (ROCE)	-25.30%	-21.60%	-25.50%	-21.50%	-38.60%	-26.40%	Upgrade
Earnings Yield	-17.78%	-16.80%	-11.27%	-13.21%	-10.42%	-7.82%	Upgrade
FCF Yield	-5.49%	-21.36%	-15.33%	0.33%	-5.79%	-7.51%	Upgrade
Buyback Yield / Dilution	-25.54%	-15.94%	-1.69%	-3.22%	-9.64%	-3.10%	Upgrade

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q